Pneumococcal infection
Not recruitingStudy on the Safety and Immune Response of V116 Vaccine for Pneumococcal Disease in Adults Aged 50 and Older
Study on the Safety and Immune Response of V116 Vaccine for Pneumococcal Disease in Adults Aged 50 and Older
- Disease:Pneumococcal infection
- Substances:Pneumococcal polysaccharide serotype 15A conjugated to CRM197Pneumococcal polysaccharide serotype 16F conjugated to CRM197+5
Germany- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Pneumococcal polysaccharide serotype 15A conjugated to CRM197
- Sponsor:Merck Sharp & Dohme LLC








